*, control period; *, after one week nivazol 400mg/day; *, after 6 weeks nivazol 800 mg/day. Normal range for plasma ACTH: 0800 h <80 ng/l; 2400 h < IO ng/l. weeks despite reducing nivazol to 200 mg twice daily and hydrocortisone to 5 mg daily, but resolved after withdrawal of nivazol.
Discussion
Nivazol was clearly highly effective in decreasing plasma ACTH concentrations and pigmentation. Its mechanism of action is probably similar to that of hydrocortisone. Both steroids directly inhibit in vitro ACTH secretion from corticotroph tumour cells removed from patients with Nelson's syndrome and block stimulation of ACTH release by ovine corticotrophin releasing factor and arginine vasopressin.3 As therapeutic plasma nivazol levels are lower than those effective in vitro, nivazol (like hydrocortisone) may also act on the hypothalamus. The unchanged cortisol profiles argue against an effect on hydrocortisone metabolism. We cannot assess whether nivazol had additional tumour stabilizing or shrinkage effects. Nivazol had significant Cushingoid side effects in our patient, even though proportionately much higher doses (1 g/day) in monkeys suppressed the hypothalamic-pituitary adrenal axis without exerting peripheral glucocorticoid effects.4 It remains to be investigated whether dosages of <400mg/day may be therapeutically useful without causing these side effects.
